Skip to main content
NCBI home page
British Journal of Clinical Pharmacology logoLink to British Journal of Clinical Pharmacology
. 1989 Feb;27(2):159–163. doi: 10.1111/j.1365-2125.1989.tb05346.x

The effects of lisuride, terguride and bromocriptine on intraocular pressure (IOP).

M R Al-Sereiti 1, P Turner 1
PMCID: PMC1379775  PMID: 2713211

Abstract

1. The effects of a single oral dose of the dopaminergic agonists lisuride (0.1 mg), terguride (0.25 mg) and bromocriptine (1.25 mg) on IOP were studied in eight normal volunteers using the non-contact tonometer. 2. Considering all post-dose measurements, compared with placebo, bromocriptine and lisuride but not terguride reduced IOP significantly in both eyes. 3. There was no significant difference between the ocular hypotensive effect of bromocriptine and lisuride. 4. Terguride reduced IOP significantly in the left eye at the 3 h time point after drug administration. 5. The result of this study confirms the reported ocular hypotensive effect of bromocriptine and showed that lisuride is as effective as bromocriptine in reducing IOP. 6. To evaluate the clinical importance of these drugs as ocular hypotensive agents other studies are needed using eye drops.

Full text

PDF
159

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Ciccarelli E., Touzel R., Besser M., Grossman A. Terguride--a new dopamine agonist drug: a comparison of its neuroendocrine and side effect profile with bromocriptine. Fertil Steril. 1988 Apr;49(4):589–594. doi: 10.1016/s0015-0282(16)59823-9. [DOI] [PubMed] [Google Scholar]
  2. Czarnecki J. S., Pilley S. F., Thompson H. S. The analysis of anisocoria. The use of photography in the clinical evaluation of unequal pupils. Can J Ophthalmol. 1979 Oct;14(4):297–302. [PubMed] [Google Scholar]
  3. Geyer O., Robinson D., Lazar M. Hypotensive effect of bromocriptine in glaucomatous eyes. J Ocul Pharmacol. 1987 Winter;3(4):291–294. doi: 10.1089/jop.1987.3.291. [DOI] [PubMed] [Google Scholar]
  4. Grolman B. A new tonometer system. Am J Optom Arch Am Acad Optom. 1972 Aug;49(8):646–660. doi: 10.1097/00006324-197208000-00005. [DOI] [PubMed] [Google Scholar]
  5. Horowski R., Wachtel H. Direct dopaminergic action of lisuride hydrogen maleate, an ergot derivative, in mice. Eur J Pharmacol. 1976 Apr;36(2):373–383. doi: 10.1016/0014-2999(76)90091-1. [DOI] [PubMed] [Google Scholar]
  6. Koller W. C., Herbster G. Terguride, a mixed dopamine agonist-antagonist, in animal models of Parkinson's disease. Neurology. 1987 Apr;37(4):723–727. doi: 10.1212/wnl.37.4.723. [DOI] [PubMed] [Google Scholar]
  7. LeWitt P. A., Gopinathan G., Ward C. D., Sanes J. N., Dambrosia J. M., Durso R., Calne D. B. Lisuride versus bromocriptine treatment in Parkinson disease: a double-blind study. Neurology. 1982 Jan;32(1):69–72. doi: 10.1212/wnl.32.1.69. [DOI] [PubMed] [Google Scholar]
  8. Lustig A. Verstärkt Bromocriptin die Wirkung augeninnendrucksenkender Mittel? Dtsch Med Wochenschr. 1983 Oct 28;108(43):1656–1657. [PubMed] [Google Scholar]
  9. Mekki Q. A., Hassan S. M., Turner P. Bromocriptine lowers intraocular pressure without affecting blood pressure. Lancet. 1983 Jun 4;1(8336):1250–1251. doi: 10.1016/s0140-6736(83)92699-5. [DOI] [PubMed] [Google Scholar]
  10. Mekki Q. A., Turner P. Stimulation of dopamine receptors (type 2) lowers human intraocular pressure. Br J Ophthalmol. 1985 Dec;69(12):909–910. doi: 10.1136/bjo.69.12.909. [DOI] [PMC free article] [PubMed] [Google Scholar]
  11. Mekki Q. A., Warrington S. J., Turner P. Bromocriptine eyedrops lower intraocular pressure without affecting prolactin levels. Lancet. 1984 Feb 4;1(8371):287–288. doi: 10.1016/s0140-6736(84)90162-4. [DOI] [PubMed] [Google Scholar]
  12. Nelson W. L., Fraunfelder F. T., Sills J. M., Arrowsmith J. B., Kuritsky J. N. Adverse respiratory and cardiovascular events attributed to timolol ophthalmic solution, 1978-1985. Am J Ophthalmol. 1986 Nov 15;102(5):606–611. doi: 10.1016/0002-9394(86)90532-5. [DOI] [PubMed] [Google Scholar]
  13. Potter D. E., Burke J. A., Chang F. W. Ocular hypotensive action of ergoline derivatives in rabbits: effects of sympathectomy and domperidone pretreatment. Curr Eye Res. 1984 Feb;3(2):307–314. doi: 10.3109/02713688408997214. [DOI] [PubMed] [Google Scholar]
  14. Potter D. E., Burke J. A. Effects of ergoline derivatives on intraocular pressure and iris function in rabbits and monkeys. Curr Eye Res. 1982;2(5):281–288. doi: 10.3109/02713688209000771. [DOI] [PubMed] [Google Scholar]
  15. Potter D. E., Shumate D. J. Cianergoline lowers intraocular pressure in rabbits and monkeys and inhibits contraction of the cat nictitans by suppressing sympathetic neuronal function. J Ocul Pharmacol. 1987 Winter;3(4):309–321. doi: 10.1089/jop.1987.3.309. [DOI] [PubMed] [Google Scholar]
  16. Shannon R. P., Mead A., Sears M. L. The effect of dopamine on the intraocular pressure and pupil of the rabbit eye. Invest Ophthalmol. 1976 May;15(5):371–380. [PubMed] [Google Scholar]
  17. Shields M. B. The non-contact tonometer. Its value and limitations. Surv Ophthalmol. 1980 Jan-Feb;24(4):211–219. doi: 10.1016/0039-6257(80)90042-9. [DOI] [PubMed] [Google Scholar]
  18. Siegel M. J., Lee P. Y., Podos S. M., Mittag T. W. Effect of topical pergolide on aqueous dynamics in normal and glaucomatous monkeys. Exp Eye Res. 1987 Feb;44(2):227–233. doi: 10.1016/s0014-4835(87)80007-6. [DOI] [PubMed] [Google Scholar]
  19. Wachtel H., Dorow R. Dual action on central dopamine function of transdihydrolisuride, a 9, 10-dihydrogenated analogue of the ergot dopamine agonist lisuride. Life Sci. 1983 Jan 24;32(4):421–432. doi: 10.1016/0024-3205(83)90089-9. [DOI] [PubMed] [Google Scholar]

Articles from British Journal of Clinical Pharmacology are provided here courtesy of British Pharmacological Society

RESOURCES